BILL · 2007–08 SESSION

HB 1356: Brand name drugs

Authorizing purchase of brand name drugs when cost-effective for all state purchased health care programs.

Summary

Where the quality of care is not diminished, the State evidence-based prescription drug program will purchase the least expensive prescription drug, whether it be a brand drug or a generic equivalent.

From the House Bill Analysis 2007 (HB 1356), written by the Legislature's nonpartisan staff. Read the full report ↗

Did not pass Did not pass · died in committee

AN ACT Relating to authorizing purchase of brand name drugs when cost-effective for all state purchased health care programs;

No recorded floor votes. This measure never reached a floor vote.

Bill numbers restart every two years, so the same number is a different bill in each session.

HB 1356 (2025–26) K-12 funding · Did not pass · died in committee
HB 1356 (2023–24) Biosimilar medicines · Did not pass · died in committee
HB 1356 (2021–22) Native American names, etc. · Enacted · Chapter 128, Laws of 2021
HB 1356 (2019–20) Peer support group privilege · Enacted · Chapter 98, Laws of 2019
HB 1356 (2017–18) Physician limited licenses · Did not pass · died in committee
HB 1356 (2015–16) Sick & safe employment leave · Did not pass · passed House, stalled in Senate
HB 1356 (2013–14) Hearing aids coverage · Did not pass · died in committee
HB 1356 (2011–12) Credit card interest rates · Did not pass · died in committee